AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2018
Jul 23, 2018
35334_dirs_2018-07-23_d9b5a44e-5fda-4315-8432-113ded553975.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-07-23
Reporting Person: PASCALE ADAM (CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-07-23 | Common Stock | P | 32259 | $0.31 | Acquired | 59648 | Direct |
More from AIM ImmunoTech Inc.
Capital/Financing Update
2026
Jun 18
Capital/Financing Update
2026
Jun 18
Regulatory Filings
2026
Jun 15
Share Issue/Capital Change
2026
Jun 11
Governance Information
2026
Jun 10
Capital/Financing Update
2026
Jun 10
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21